Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL1333 Safety and PK Study in Healthy Subjects and Mitochondrial Disease Patients
NCT03888716Phase 1Completed
- Sponsor
- Abliva AB
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of napazimone in primary mitochondrial disease (PMD) (3 arms), sponsored by Abliva AB. Primary endpoints: Incidence and severity of Adverse Events at Day 15 and Incidence of laboratory abnormalities at Day 15. Started Mar 2019; status: completed.
02
Drugs
napazimone
03
Conditions
primary mitochondrial disease (PMD)
Beyond the preview
Go deeper on NCT03888716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888716.